184 related articles for article (PubMed ID: 12750398)
1. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.
Bai XF; Liu J; Li O; Zheng P; Liu Y
J Clin Invest; 2003 May; 111(10):1487-96. PubMed ID: 12750398
[TBL] [Abstract][Full Text] [Related]
2. Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy.
Bai XF; Liu JQ; Joshi PS; Wang L; Yin L; Labanowska J; Heerema N; Zheng P; Liu Y
Cancer Res; 2006 Aug; 66(16):8241-9. PubMed ID: 16912204
[TBL] [Abstract][Full Text] [Related]
3. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
4. Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.
Wang L; Liu JQ; Talebian F; El-Omrani HY; Khattabi M; Yu L; Bai XF
Eur J Immunol; 2010 Sep; 40(9):2569-79. PubMed ID: 20662098
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
6. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815.
Van den Eynde B; Mazarguil H; Lethé B; Laval F; Gairin JE
Eur J Immunol; 1994 Nov; 24(11):2740-5. PubMed ID: 7525302
[TBL] [Abstract][Full Text] [Related]
7. T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.
Bruns M; Wanger J; Schumacher U; Deppert W
Oncotarget; 2016 Oct; 7(40):64543-64559. PubMed ID: 27579535
[TBL] [Abstract][Full Text] [Related]
8. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
Matsui K; O'Mara LA; Allen PM
Int Immunol; 2003 Jul; 15(7):797-805. PubMed ID: 12807818
[TBL] [Abstract][Full Text] [Related]
9. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
10. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
[TBL] [Abstract][Full Text] [Related]
11. On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires.
Sarma S; Bai XF; Liu JQ; May KF; Zheng P; Liu Y
Cancer Res; 2003 Sep; 63(18):6051-5. PubMed ID: 14522934
[TBL] [Abstract][Full Text] [Related]
12. Minimal tolerance to a tumor antigen encoded by a cancer-germline gene.
Huijbers IJ; Soudja SM; Uyttenhove C; Buferne M; Inderberg-Suso EM; Colau D; Pilotte L; Powis de Tenbossche CG; Chomez P; Brasseur F; Schmitt-Verhulst AM; Van den Eynde BJ
J Immunol; 2012 Jan; 188(1):111-21. PubMed ID: 22140254
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of in vitro and in vivo functions of a tumor-specific T suppressor cell clone from a BALB/c mouse bearing the syngeneic ADJ-PC-5 plasmacytoma.
Haubeck HD; Kölsch E
J Immunol; 1985 Dec; 135(6):4297-302. PubMed ID: 2415609
[TBL] [Abstract][Full Text] [Related]
14. Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs.
Liu JQ; Joshi PS; Wang C; El-Omrani HY; Xiao Y; Liu X; Hagan JP; Liu CG; Wu LC; Bai XF
J Immunol; 2010 May; 184(10):5435-43. PubMed ID: 20404277
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T lymphocyte lines reactive against murine plasmacytoma antigens: dissociation of cytotoxicity and Lyt-2 expression.
Giorgi JV; Zawadzki JA; Warner NL
Eur J Immunol; 1982 Oct; 12(10):831-7. PubMed ID: 6184236
[TBL] [Abstract][Full Text] [Related]
16. Induction of rapid apoptosis for class I MHC molecule-restricted CD8(+) HIV-1 gp160-specific murine activated CTLs by free antigenic peptide in vivo.
Nakagawa Y; Shimizu M; Norose Y; Takahashi M; Takahashi H
Int Immunol; 2013 Jan; 25(1):11-24. PubMed ID: 22945875
[TBL] [Abstract][Full Text] [Related]
17. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
Bogen B
Eur J Immunol; 1996 Nov; 26(11):2671-9. PubMed ID: 8921954
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.
Sarma S; Guo Y; Guilloux Y; Lee C; Bai XF; Liu Y
J Exp Med; 1999 Mar; 189(5):811-20. PubMed ID: 10049945
[TBL] [Abstract][Full Text] [Related]
19. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
20. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
